Impulse control disorder in early Parkinson’s disease: Follow-up study
Objective: To assess frequency of impulse control disorder (ICD) in a cohort of patients with early stage of Parkinson's disease (PD), to analyze clinical and…Association of the DRD2 (CA) n and DRD3 Ser9Gly polymorphisms with Parkinson’s disease and response of dopamine agonists
Objective: To investigate the association between dopamine receptor D types 2(DRD2) (CA)n and types 3 (DRD3) Ser9Gly polymorphisms and the risk of Parkinson's disease (PD),…Technology use and impulse control disorders (ICDs) in patients with Parkinson’s disease (PD)
Objective: To ascertain the prevalence of problematic technology use (Technology-related ICDs, Tech-ICDs) in patients with PD. Background: ICDs are a known complication of PD drugs…Drug safety in the pharmacotherapy of Parkinson’s disease
Objective: Detection of the most common and most serious drug-related problems in the pharmacotherapy of Parkinson's disease (PD), particularly with focus on interactions and contraindications…Dropped head syndrome in parkinsonism: Two treatable etiologies not to miss
Objective: To report the etiology of treatable head drop in Parkinson's disease (PD): one patient from rotigotine patch and the other two from neck extensor…Peri-operative dopaminergic replacement protocol with rotigotine in Parkinson’s disease patients
Objective: To evaluate the accomplishment of a peri-operative dopaminergic replacement protocol established in our centre from 2011 to 2014, and analyse the main factors associated…The relationship between impulse control disorders and dyskinesia in Parkinson´s disease: The ALTHEA study
Objective: To report (1) the relationship between the occurrence of impulse control disorders (ICDs) and dyskinesias, and (2) the correlations between specific ICDs and the…The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson’s disease: Experience from a case report
Objective: To describe the clinical effects of combined natural dopaminergic drugs with conventional levodopa therapy in a PD patient with motor and non-motor complications. Background:…The dopamine agonist withdrawal syndrome rating scale (DAWS-RS): Initial development of a new non-motor scale
Objective: To describe the development of the dopamine agonist withdrawal syndrome (DAWS) rating scale (DAWS-RS), a new questionnaire designed to evaluate the symptoms, severity, and…Improving drug discovery using brain oscillations as biomarkers of Parkinson’s disease
Objective: The aim of this study was to assess the use of cortical oscillations as translational biomarkers for drug development for the motor symptoms of…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.